Defence Therapeutics Inc., a clinical-stage biotechnology company specializing in advanced endosomal escape technologies, has opened its first U.S. laboratory in the Boston-Cambridge area. The strategic expansion represents the Montreal-based company's initial physical presence in the United States and positions it within one of the world's most prominent biotech ecosystems.
Strategic Laboratory Expansion
The new laboratory, located at Cambridge Scientific Labs in Watertown, will serve as a dedicated facility for advancing Defence Therapeutics' proprietary Accum® technology platform. The technology enables precision delivery of radio-immuno-conjugates and antibody-drug conjugates (ADCs) in their intact form to target cells, potentially increasing efficacy and potency against cancer.
"Our expansion into the Boston-Cambridge area is a significant milestone for Defence Therapeutics," said Sebastien Plouffe, CEO of Defence Therapeutics. "Establishing a U.S. laboratory positions us at the heart of the global biotech community and supports our mission to advance the Accum® platform for next-generation ADCs."
Technology Platform Focus
The Accum® technology represents the core of Defence Therapeutics' platform, designed to address key challenges in targeted cancer therapy delivery. The technology's endosomal escape capabilities aim to improve the delivery of therapeutic payloads directly to cancer cells while maintaining the structural integrity of the drug conjugates.
The company is developing next-generation radio-immuno-conjugate and ADC products using this proprietary platform. By establishing operations in the Boston-Cambridge area, Defence Therapeutics gains access to the region's extensive scientific resources and potential collaboration opportunities within the established biotech ecosystem.
Future Expansion Plans
The Cambridge Scientific Labs location will function as a short-term operational base while the company evaluates options for a long-term facility in the area. This approach allows Defence Therapeutics to establish its presence in the U.S. market while conducting due diligence on permanent facility options.
Plouffe emphasized the company's commitment to deepening its presence in the region, stating, "We look forward to deepening our presence in the region as we continue to grow and pursue a long-term facility in this dynamic market."
The expansion reflects Defence Therapeutics' broader strategy to advance its clinical-stage programs and strengthen its position in the competitive ADC development landscape. The company trades on multiple exchanges including the Canadian Securities Exchange (CSE: DTC), OTCQB (DTCFF), and Frankfurt Stock Exchange (FSE: DTC).
